Loading
A phase 2 trial in triple-negative breast cancer, run by Memorial Sloan Kettering Cancer Center, now recruiting.
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease is a phase 2, randomised interventional study registered as NCT03808337 by Memorial Sloan Kettering Cancer Center, with a registry enrolment figure of 145 participants, started 2019-01-16 and due to reach its primary completion in 2027-01. Interventions recorded: Stereotactic Body Radiotherapy/SBRT; Systemic Therapy/Standard of Care. Conditions listed: Triple Negative Breast Cancer; Non Small Cell Lung Cancer; Metastatic Breast Cancer; Metastatic Non-Small Cell Lung Carcinoma. Sites: United States. No results are recorded here; the registry entry is the source.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.